Project Grant R01GM157259

Award Date 6/1/25
Completion Date 2/28/29
Dollars Obligated $337K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $1,095,274 to develop complementary biotherapeutic delivery platforms for enabling gene re-delivery. The award, effective August 1, 2024 through May 31, 2029, aims to pioneer innovative delivery strategies that overcome biological barriers and modulate immune responses to improve the effectiveness of adeno-associated virus...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,503,949.00 to Rockefeller University for a research project titled "Applying RNA Logic in Space and Time to Neurologic Disease." The project aims to develop new techniques and concepts to discover therapeutic targets for neurological diseases. Key focus areas include...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $382,801 to the University of California, Los Angeles (UCLA) to develop synthetic RNA organelles for spatiotemporal separation, control, and monitoring in living cells. The project aims to establish engineered RNA nanostructures, called "nanostars," as a platform to build customizable RNA organelles that can be used to...
The federal Project Grant award R21NS141110, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a synthetic biological system to manipulate subcellular RNAs and proteins in specific neuron subtypes and contexts. The $481,250 award to President and Fellows of Harvard College will fund the creation of tools to selectively traffic proteins to...
This $367,059 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to develop a better understanding of the genomic, epigenomic, and transcriptomic outcomes of gene therapy. The research aims to explore the long-term effects of vector integration, the impact of cell/tissue type and promoters on vector behavior, and the host response to different gene therapy delivery...
This Project Grant award under the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of prototype mouse models to investigate the SEND (Selective Endogenous Encapsidation for Cellular Delivery) system for mRNA delivery and gene therapy applications. The $330,025 award, provided by the Department of Health and Human Services (HHS), will fund the creation of three genetically engineered mouse models to...
This federal Project Grant award, valued at $540,524 and effective from March 1, 2025 to February 28, 2029, was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program. The primary objective of this award is to develop an enhanced RNA switch technology based on the T3H38 ribozyme, which can enable precise dose control and temporal regulation...
This $821,998 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to enhance the delivery of non-viral, neuron-specific molecules across species in the central nervous system. The funded research project will further characterize the capabilities of a novel 15-amino-acid peptide, N1, to selectively target and deliver a range of molecules (e.g. sensor dyes, mRNA, DNA, proteins) into neurons across multiple...
This federal Project Grant award for $387,500.00, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859), supports research to understand the roles of microRNAs in animal development. The long-term goal of this research program is to elucidate the gene regulatory mechanisms that enable a single-celled zygote to develop into a multicellular organism. Specifically, the project focuses on studying the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,445 to Endura Therapeutics Inc. aims to develop a next-generation sequencing platform for discovering small molecules that target RNA. The project addresses two key challenges: demonstrating that small molecules binding to messenger RNA can modulate protein expression in cells, and developing a high-throughput screening method to identify such molecules and their optimal...

This $337,088 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to establish a versatile platform for delivering RNA therapeutics specifically to the central nervous system (CNS). The project seeks to develop an innovative delivery system that integrates high-efficiency RNA encapsulation, precise cell targeting, and minimal cellular disruption. The key objectives are to engineer RNA-encapsulating capsids with endosomal escape capabilities, develop cell-specific capsid targeting, and validate the technology's efficacy and safety through in vivo studies in cortical and spinal tissues. Upon successful completion, this project will deliver a transformative RNA delivery system that provides researchers unprecedented control and specificity in modulating gene expression within the CNS, enabling advancements in basic neuroscience research and the development of novel therapeutic strategies for neurological disorders. The award period runs from June 1, 2025, to February 28, 2029.

Generated 6/17/25, 3:29 AM